Abstract
Background: Hypertrophic Cardiomyopathy (HCM) is the most common inherited Cardiomyopathy. The hallmark of HCM is myocardial fibrosis that contributes to heart failure, arrhythmias and sudden cardiac death.
Objective: Currently, there are no reliable serum biomarkers for the detection of myocardial fibrosis, while cardiac magnetic resonance (CMR) is an imaging technique to detect myocardial fibrosis. MicroRNAs (miRNAs) have been increasingly suggested as biomarkers in cardiovascular diseases. However, in HCM there is as yet no identified and verified specific circulating miRNA signature.
Methods: We conducted a review of the literature to identify the studies that indicate the possible roles of miRNAs in HCM.
Results: From studies in transgenic mice with HCM, miR-1, -133 may identify HCM in the early asymptomatic phase. Human miR-29a could be used as a circulating biomarker for detection of both myocardial hypertrophy and fibrosis in HCM, while it could also have a possible additional role in discrimination of hypertrophic obstructive cardiomyopathy from non-obstructive HCM. Additionally, miR-29a-3p is associated with diffuse myocardial fibrosis in HCM, while miR-1-3p could discriminate end-stage HCM from dilated cardiomyopathy and left ventricle dilation. Another role of miRNAs could also be the contribution in the differential diagnosis between HCM and phenocopies. Moreover, miRNA- targeted therapy (miR-133 mimics) is promising in inhibiting cardiac hypertrophy, but this is still in the early stages.
Conclusion: A more reliable and specific signature of miRNAs is expected with forthcoming studies in samples from HCM patients and correlation of miRNAs with CMR and serum markers of fibrosis may implicate novel diagnostic and therapeutic pathways.
Keywords: Hypertrophic Cardiomyopathy, cardiomyopathies, miRNAs, fibrosis, hypertrophy, biomarkers.
Current Medicinal Chemistry
Title:MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art
Volume: 28 Issue: 36
Author(s): Andreas Angelopoulos, Evangelos Oikonomou*, Georgia Vogiatzi, Alexios Antonopoulos, Sotirios Tsalamandris, Christos Georgakopoulos, Paraskevi Papanikolaou, George Lazaros, Georgios Charalambous, Gerasimos Siasos, Charalambos Vlachopoulos and Dimitris Tousoulis
Affiliation:
- EKKAN (Unit for the Athletes and for Hereditary Cardiovascular Diseases), 1st Department of Cardiology, Hippokration Hospital, Medical School of National and Kapodistrian University of Athens, Athens,Greece
Keywords: Hypertrophic Cardiomyopathy, cardiomyopathies, miRNAs, fibrosis, hypertrophy, biomarkers.
Abstract:
Background: Hypertrophic Cardiomyopathy (HCM) is the most common inherited Cardiomyopathy. The hallmark of HCM is myocardial fibrosis that contributes to heart failure, arrhythmias and sudden cardiac death.
Objective: Currently, there are no reliable serum biomarkers for the detection of myocardial fibrosis, while cardiac magnetic resonance (CMR) is an imaging technique to detect myocardial fibrosis. MicroRNAs (miRNAs) have been increasingly suggested as biomarkers in cardiovascular diseases. However, in HCM there is as yet no identified and verified specific circulating miRNA signature.
Methods: We conducted a review of the literature to identify the studies that indicate the possible roles of miRNAs in HCM.
Results: From studies in transgenic mice with HCM, miR-1, -133 may identify HCM in the early asymptomatic phase. Human miR-29a could be used as a circulating biomarker for detection of both myocardial hypertrophy and fibrosis in HCM, while it could also have a possible additional role in discrimination of hypertrophic obstructive cardiomyopathy from non-obstructive HCM. Additionally, miR-29a-3p is associated with diffuse myocardial fibrosis in HCM, while miR-1-3p could discriminate end-stage HCM from dilated cardiomyopathy and left ventricle dilation. Another role of miRNAs could also be the contribution in the differential diagnosis between HCM and phenocopies. Moreover, miRNA- targeted therapy (miR-133 mimics) is promising in inhibiting cardiac hypertrophy, but this is still in the early stages.
Conclusion: A more reliable and specific signature of miRNAs is expected with forthcoming studies in samples from HCM patients and correlation of miRNAs with CMR and serum markers of fibrosis may implicate novel diagnostic and therapeutic pathways.
Export Options
About this article
Cite this article as:
Angelopoulos Andreas , Oikonomou Evangelos *, Vogiatzi Georgia , Antonopoulos Alexios , Tsalamandris Sotirios , Georgakopoulos Christos , Papanikolaou Paraskevi , Lazaros George , Charalambous Georgios , Siasos Gerasimos , Vlachopoulos Charalambos and Tousoulis Dimitris , MicroRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art, Current Medicinal Chemistry 2021; 28 (36) . https://dx.doi.org/10.2174/0929867328666210405122703
DOI https://dx.doi.org/10.2174/0929867328666210405122703 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Free Radicals in Diseases and Potential Role of Phytoconstituents-A Cause with Emerging Importance
Current Chemical Biology Potential Relevance of Melatonin Against Some Infectious Agents: A Review and Assessment of Recent Research
Current Medicinal Chemistry Long-circulating Targeted Nanoparticles for Cancer Therapy
Current Nanoscience The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Gender Differences in Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Irbesartan: Second Generation of ARB as Metabosartan
Current Hypertension Reviews Retraction Note: Phytochemicals from Plants to Combat Cardiovascular Disease
Current Medicinal Chemistry Protein Synthesis and Assembly in Mitochondrial Disorders
Current Topics in Medicinal Chemistry Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress
Current Pharmaceutical Design Pathogenic Mechanisms of Trimethylamine N-Oxide-induced Atherosclerosis and Cardiomyopathy
Current Vascular Pharmacology Sirtuins: Novel Players in Male Reproductive Health
Current Medicinal Chemistry Current Nervous System Related Drug Targets for the Treatment of Amyotrophic Lateral Sclerosis
Current Pharmaceutical Design Pediatric Immune Dysfunction and Health Risks Following Early-Life Immune Insult
Current Pediatric Reviews Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews Algorithms and Criteria for Transcatheter Aortic Valve Replacement Patient Selection: Current Status and Future Trends
Current Pharmaceutical Design Ionophores as Potent Anti-malarials: A Miracle in the Making
Current Topics in Medicinal Chemistry Neopterin as a Marker for Immune System Activation
Current Drug Metabolism Effect of Aging on Metabolic Pathways in Endothelial Progenitor Cells
Current Pharmaceutical Design Phosphodiesterase-5 Inhibitors: Future Perspectives
Current Pharmaceutical Design Nanoceria: Synthesis and Biomedical Applications
Current Nanoscience